Skip to main content

Table 5 Subgroup analysis for the effect of statin therapy on stoke

From: Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials

Subgroup Value Reference Statin Control Relative risk (95% CI) p value Heterogeneity p value for heterogeneity
    (Event/total) (Event/total)     
Mean Age > = 60 29,33,34 50/2768 72/2789 0.71[0.50,1.01] 0.058 0% 0.732
  <60 24 7/433 4/431 1.74[0.51,5.91] 0.373 - -
Cardiovascular History Yes 29,34 40/1130 58/1160 0.71[0.48,1.05] 0.088 0% 0.429
  No 26 37/3533 57/3663 0.67[0.45,1.02] 0.059 - -
Baseline GFR > = 60 26 37/3533 57/3663 0.67[0.45,1.02] 0.059 - -
  <60 29,33 21/1924 26/1922 0.82[0.46,1.45] 0.488 0% 0.63
Baseline Creatinine > = 1.5 29 11/286 12/293 0.94[0.42,2.09] 0.878   
  <1.5 24,34 36/1277 50/1298 0.90[0.36,2.23] 0.815 54.9% 0.14
Baseline LDL Cholesterol > = 3.0 24,29,34 47/1563 62/1591 0.82[0.51,1.30] 0.387 20.3% 0.29
  <3.0 33 10/1638 14/1429 0.71[0.32,1.60] 0.407 - -
LDL Cholesterol Lowering > = 30% 29,33 21/1924 26/1922 0.82[0.46,1.45] 0.488 0% 0.63
  <30% 24,26 44/3966 61/4094 0.90[0.38,2.14] 0.818 52.2% 0.15
Follow-up time > = 3 24,26,29,34 84/5096 119/5254 0.73[0.55,0.96] 0.023 0% 0.43
  <3 33 10/1638 14/1629 0.71[0.32,1.59] 0.407 - -
  1. Abbreviations: CI confidential interval, GFR glomerular filtration rate, LDL low density lipoprotein.